Beam Therapeutics Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Beam Therapeutics's estimated revenue is currently $16.4M per year.
- Beam Therapeutics received $135.0M in venture funding in March 2019.
- Beam Therapeutics's estimated revenue per employee is $145398
- Beam Therapeutics's total funding is $222M.
- Beam Therapeutics has 113 Employees.
- Beam Therapeutics grew their employee count by 163% last year.
- Beam Therapeutics currently has 4 job openings.
|Francine Gregoire||VP Liver Diseases|
|Delai Chen||Associate Director, Nanoparticle formulation|
|Dana Levasseur||Vice President, Hematology|
|Courtney Wallace||SVP/Head of Business Development and Strategy|
|Stephen Cavnar||Director, New Product Planning|
|Susan O'Connor||Chief Human Resources Officer|
|Matt Lee||Associate Director, Structural Biology & Protein Sciences|
|Charlie Liu||Director, Business Development & Operations|
|Brian Busser||Senior Director|
|Carlo Zambonelli||Associate Director of Analytical Development|
What Is Beam Therapeutics?
Beam Therapeutics is developing precision genetic medicines for serious diseases. Co-founded by scientific pioneers known for advancing CRISPR gene editing, were the first company to pursue development of new therapies using CRISPR base editing technology. We aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. WHO WE ARE Beam is creating precision genetic medicines through base editing WHY WE DO IT Our dream is to provide life-long cures for patients suffering from serious diseases WHO WE ARE AND HOW WE WORK TOGETHER The Beam Team: A community of fearless innovators Rigorous and honest in our research Listening with open minds Committed to each otherkeywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Beam Therapeutics News
CAMBRIDGE, Mass.--(BUSINESS WIRE)--. Beam Therapeutics, a biotechnology company developing precision genetic medicines through ...
LeSauteur comes out of the Human Health Therapeutics Research Center ... Cambridge, Massachusetts-based Beam Therapeutics has named ...
This year, Beam Therapeutics has been the largest beneficiary of venture capital, after raising $135m in its Series B financing round. However ...
Beam Therapeutics Funding
|2018-05-15||$87.0M||A||F-Prime Capital Partners||Article|